Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Anirvan Ghosh named head of discovery for CNS at Roche

This article was originally published in Scrip

Executive Summary

Roche has named Dr Anirvan Ghosh head of discovery for central nervous system (CNS). He will oversee discovery research in the CNS Disease and Translational Area with an emphasis on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression and neurodevelopment disorders. Dr Ghosh, who will relocate to Basel, Switzerland, joins Roche's Pharma Research and Early Development organisation from the University of California San Diego, where he has been the Stephen Kuffler professor of neurobiology since 2003; chair of the neurobiology section, division of biological sciences, since 2008; and co-director of the Center for Neural Circuits and Behavior since 2009.

You may also be interested in...

Daiichi Sankyo Enters Europe's Cholesterol Market

The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.

CSL Behring And SAB Explore Polyclonal Antibodies For COVID-19

CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts